Brief: Aeterna Zentaris Announces Exclusive License Agreement And Research Contract With Julius-Maximilians-University Wuerzburg For Development Of A Potential Oral Prophylactic Bacterial Vaccine Against Covid-19
15/03/2021 12:50
March 15 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* AETERNA ZENTARIS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT AND
RESEARCH CONTRACT WITH JULIUS-MAXIMILIANS-UNIVERSITY WUERZBURG
FOR DEVELOPMENT OF A POTENTIAL ORAL PROPHYLACTIC BACTERIAL
VACCINE AGAINST COVID-19
* AETERNA ZENTARIS INC - ON MARCH 14, 2021, COMPANY
EXERCISED
OPTION AND ENTERED INTO LICENSE AGREEMENT
* AETERNA ZENTARIS INC - WILL PAY UP-FRONT PAYMENT OF EUR
140,000,
MAKE CERTAIN MILESTONES PAYMENTS
Source text for Eikon: ID:nGNX6s7LrR
Further company coverage: AEZS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on COSCIENS Biopharma
See all newsBrief: COSCIENS Acquires Nualtis Corp
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update